Implications of genetic polymorphisms in drug transporters for pharmacotherapy

Kalow, 1999, Repeat administration of drugs as a means to assess the genetic component in pharmacological variability, Pharmacology, 58, 281, 10.1159/000028292 Meyer, 2004, Pharmacogenetics—five decades of therapeutic lessons from genetic diversity, Nat. Rev. Genet., 5, 669, 10.1038/nrg1428 Weinshilboum, 2003, Inheritance and drug response, N. Engl. J. Med., 348, 529, 10.1056/NEJMra020021 Evans, 2003, Pharmacogenomics—drug disposition, drug targets, and side effects, N. Engl. J. Med., 348, 538, 10.1056/NEJMra020526 Fischer, 2005, Efflux transporters and their clinical relevance, Mini. Rev. Med. Chem., 5, 183, 10.2174/1389557053402756 Gerloff, 2004, Impact of genetic polymorphisms in transmembrane carrier-systems on drug and xenobiotic distribution, Naunyn. Schmiedebergs Arch. Pharmacol., 369, 69, 10.1007/s00210-003-0813-5 Kim, 2002, Transporters and xenobiotic disposition, Toxicology, 181–182, 291, 10.1016/S0300-483X(02)00296-2 Kerb, 2001, ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2, Pharmacogenomics, 2, 51, 10.1517/14622416.2.1.51 Roden, 2002, The genetic basis of variability in drug responses, Nat. Rev. Drug Discov., 1, 37, 10.1038/nrd705 Ayrton, 2001, Role of transport proteins in drug absorption, distribution and excretion, Xenobiotica, 31, 469, 10.1080/00498250110060969 Inui, 2000, Cellular and molecular aspects of drug transport in the kidney, Kidney Int., 58, 944, 10.1046/j.1523-1755.2000.00251.x Dresser, 2001, Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters, J. Pharm. Sci., 90, 397, 10.1002/1520-6017(200104)90:4<397::AID-JPS1000>3.0.CO;2-D Borst, 2002, Mammalian ABC transporters in health and disease, Annu. Rev. Biochem., 71, 537, 10.1146/annurev.biochem.71.102301.093055 Bodo, 2003, The role of multidrug transporters in drug availability, metabolism and toxicity, Toxicol. Lett., 140–141, 133, 10.1016/S0378-4274(02)00497-6 Kullak-Ublick, 2004, Enterohepatic bile salt transporters in normal physiology and liver disease, Gastroenterology, 126, 322, 10.1053/j.gastro.2003.06.005 Chandra, 2004, The complexities of hepatic drug transport: current knowledge and emerging concepts, Pharm. Res., 21, 719, 10.1023/B:PHAM.0000026420.79421.8f Hediger, 2004, The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins introduction, Pflugers Arch., 447, 465, 10.1007/s00424-003-1192-y Jonker, 2004, Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3), J. Pharmacol. Exp. Ther., 308, 2, 10.1124/jpet.103.053298 Koepsell, 2004, Polyspecific organic cation transporters: their functions and interactions with drugs, Trends Pharmacol. Sci., 25, 375, 10.1016/j.tips.2004.05.005 Miyazaki, 2004, The multispecific organic anion transporter family: properties and pharmacological significance, Trends Pharmacol. Sci., 25, 654, 10.1016/j.tips.2004.10.006 You, 2004, The role of organic ion transporters in drug disposition: an update, Curr. Drug Metab., 5, 55, 10.2174/1389200043489207 Tirona, 2002, Pharmacogenomics of organic anion-transporting polypeptides (OATP), Adv. Drug Deliv. Rev., 54, 1343, 10.1016/S0169-409X(02)00077-7 Pauli-Magnus, 2003, Pharmacogenetics of hepatocellular transporters, Pharmacogenetics, 13, 189, 10.1097/00008571-200304000-00003 Ieiri, 2004, The MDR1 (ABCB1) gene polymorphism and its clinical implications, Clin. Pharmacokinet., 43, 553, 10.2165/00003088-200443090-00001 Ishikawa, 2004, Pharmacogenomics of drug transporters: a new approach to functional analysis of the genetic polymorphisms of ABCB1 (P-glycoprotein/MDR1), Biol. Pharm. Bull., 27, 939, 10.1248/bpb.27.939 Marzolini, 2004, Pharmacogenomics of the OATP and OAT families, Pharmacogenomics, 5, 273, 10.1517/phgs.5.3.273.29831 Sakaeda, 2004, Pharmacogenetics of drug transporters and its impact on the pharmacotherapy, Curr. Top. Med. Chem., 4, 1385, 10.2174/1568026043387692 Woodahl, 2004, The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function, Curr. Drug Metab., 5, 11, 10.2174/1389200043489108 Dietrich, 2003, ABC of oral bioavailability: transporters as gatekeepers in the gut, Gut, 52, 1788, 10.1136/gut.52.12.1788 Schinkel, 1999, P-Glycoprotein, a gatekeeper in the blood–brain barrier, Adv. Drug Deliv. Rev., 36, 179, 10.1016/S0169-409X(98)00085-4 Graff, 2004, Drug transport at the blood–brain barrier and the choroid plexus, Curr. Drug Metab., 5, 95, 10.2174/1389200043489126 Syme, 2004, Drug transfer and metabolism by the human placenta, Clin. Pharmacokinet., 43, 487, 10.2165/00003088-200443080-00001 Huisman, 2002, Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs, AIDS, 16, 2295, 10.1097/00002030-200211220-00009 Meaden, 2002, P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals, J. Antimicrob. Chemother., 50, 583, 10.1093/jac/dkf161 Sadeque, 2000, Increased drug delivery to the brain by P-glycoprotein inhibition, Clin. Pharmacol. Ther., 68, 231, 10.1067/mcp.2000.109156 Greiner, 1999, The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin, J. Clin. Invest., 104, 147, 10.1172/JCI6663 Johne, 1999, Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum), Clin. Pharmacol. Ther., 66, 338, 10.1053/cp.1999.v66.a101944 Becquemont, 2001, Effect of grapefruit juice on digoxin pharmacokinetics in humans, Clin. Pharmacol. Ther., 70, 311, 10.1016/S0009-9236(01)13478-8 Gonzalez, 1988, Characterization of the common genetic defect in humans deficient in debrisoquine metabolism, Nature, 331, 442, 10.1038/331442a0 Saito, 2002, Catalog of 238 variations among six human genes encoding solute carriers (hSLCs) in the Japanese population, J. Hum. Genet., 47, 576, 10.1007/s100380200088 Saito, 2002, Identification of 779 genetic variations in eight genes encoding members of the ATP-binding cassette, subfamily C (ABCC/MRP/CFTR), J. Hum. Genet., 47, 147, 10.1007/s100380200018 Saito, 2002, Three hundred twenty-six genetic variations in genes encoding nine members of ATP-binding cassette, subfamily B (ABCB/MDR/TAP), in the Japanese population, J. Hum. Genet., 47, 38, 10.1007/s10038-002-8653-6 Iida, 2001, Catalog of 258 single-nucleotide polymorphisms (SNPs) in genes encoding three organic anion transporters, three organic anion-transporting polypeptides, and three NADH:ubiquinone oxidoreductase flavoproteins, J. Hum. Genet., 46, 668, 10.1007/s100380170019 Ishikawa, 2004, The genetic polymorphism of drug transporters: functional analysis approaches, Pharmacogenomics, 5, 67, 10.1517/phgs.5.1.67.25683 Ishikawa, 2004, Functional evaluation of ABCB1 (P-glycoprotein) polymorphisms: high-speed screening and structure–activity relationship analyses, Drug Metab. Pharmacokinet., 19, 1, 10.2133/dmpk.19.1 Conrad, 2001, Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution, J. Hum. Genet., 46, 656, 10.1007/s100380170017 Kim, 2001, Identification of functionally variant MDR1 alleles among European Americans and African Americans, Clin. Pharmacol. Ther., 70, 189, 10.1067/mcp.2001.117412 Tirona, 2001, Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African–Americans, J. Biol. Chem., 276, 35669, 10.1074/jbc.M103792200 Kerb, 2002, Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences, Pharmacogenetics, 12, 591, 10.1097/00008571-200211000-00002 Michalski, 2002, A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter, J. Biol. Chem., 277, 43058, 10.1074/jbc.M207735200 Nozawa, 2002, Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis, J. Pharmacol. Exp. Ther., 302, 804, 10.1124/jpet.302.2.804 Kroetz, 2003, Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene, Pharmacogenetics, 13, 481, 10.1097/00008571-200308000-00006 Morita, 2003, Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities, Biochem. Pharmacol., 65, 1843, 10.1016/S0006-2952(03)00178-3 Takeuchi, 2003, Decreased function of genetic variants, Pro283Leu and Arg287Gly, in human organic cation transporter hOCT1, Drug Metab. Pharmacokinet., 18, 409, 10.2133/dmpk.18.409 Iwai, 2004, Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C), Pharmacogenetics, 14, 749, 10.1097/00008571-200411000-00006 Kawasaki, 2004, Functional characterization of human organic cation transporter OCTN1 single nucleotide polymorphisms in the Japanese population, J. Pharm. Sci., 93, 2920, 10.1002/jps.20190 Sakata, 2004, Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions, Biochem. Biophys. Res. Commun., 313, 789, 10.1016/j.bbrc.2003.11.175 Hoffmeyer, 2000, Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo, Proc. Natl Acad. Sci. USA, 97, 3473, 10.1073/pnas.050585397 Hitzl, 2001, The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells, Pharmacogenetics, 11, 293, 10.1097/00008571-200106000-00003 Tanabe, 2001, Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene, J. Pharmacol. Exp. Ther., 297, 1137 Drescher, 2002, MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine, Br. J. Clin. Pharmacol., 53, 526, 10.1046/j.1365-2125.2002.01591.x Moriya, 2002, Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects, Biol. Pharm. Bull., 25, 1356, 10.1248/bpb.25.1356 Nakamura, 2002, Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects, Clin. Pharmacol. Ther., 71, 297, 10.1067/mcp.2002.122055 Siegmund, 2002, The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol, Clin. Pharmacol. Ther., 72, 572, 10.1067/mcp.2002.127739 Goto, 2002, C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation, Pharmacogenetics, 12, 451, 10.1097/00008571-200208000-00005 Oselin, 2003, Quantitative determination of MDR1 mRNA expression in peripheral blood lymphocytes: a possible role of genetic polymorphisms in the MDR1 gene, Eur. J. Clin. Invest., 33, 261, 10.1046/j.1365-2362.2003.01133.x Hitzl, 2004, Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1), Pharmacogenetics, 14, 309, 10.1097/00008571-200405000-00006 Lang, 2004, Genetic polymorphisms in the multidrug resistance-associated protein 3 (ABCC3, MRP3) gene and relationship to its mRNA and protein expression in human liver, Pharmacogenetics, 14, 155, 10.1097/00008571-200403000-00003 Kobayashi, 2005, Functional assessment of abcg2 (bcrp) gene polymorphisms to protein expression in human placenta, Drug Metab. Dispos., 33, 94, 10.1124/dmd.104.001628 Calado, 2002, Influence of functional MDR1 gene polymorphisms on P-glycoprotein activity in CD34+ hematopoietic stem cells, Haematologica, 87, 564 Oselin, 2003, MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes, Fundam. Clin. Pharmacol., 17, 463, 10.1046/j.1472-8206.2003.00163.x Morita, 2003, MDR1 genotype-related duodenal absorption rate of digoxin in healthy Japanese subjects, Pharm. Res., 20, 552, 10.1023/A:1023282312757 Nishizato, 2003, Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics, Clin. Pharmacol. Ther., 73, 554, 10.1016/S0009-9236(03)00060-2 Mwinyi, 2004, Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics, Clin. Pharmacol. Ther., 75, 415, 10.1016/j.clpt.2003.12.016 Niemi, 2004, High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1), Pharmacogenetics, 14, 429, 10.1097/01.fpc.0000114750.08559.32 Fellay, 2002, Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study, Lancet, 359, 30, 10.1016/S0140-6736(02)07276-8 Illmer, 2002, MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients, Cancer Res., 62, 4955 Asano, 2003, ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation, Pharmacogenetics, 13, 675, 10.1097/00008571-200311000-00003 Brumme, 2003, Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response, AIDS, 17, 201, 10.1097/00002030-200301240-00010 Siddiqui, 2003, Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1, N. Engl. J. Med., 348, 1442, 10.1056/NEJMoa021986 Kajinami, 2004, Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner, Am. J. Cardiol., 93, 1046, 10.1016/j.amjcard.2004.01.014 Tachibana-Iimori, 2004, Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors, Drug Metab. Pharmacokinet., 19, 375, 10.2133/dmpk.19.375 Zheng, 2002, The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients, Hum. Immunol., 63, 765, 10.1016/S0198-8859(02)00426-3 Zhu, 2004, Influence of single-nucleotide polymorphisms in the multidrug resistance-1 gene on the cellular export of nelfinavir and its clinical implication for highly active antiretroviral therapy, Antivir. Ther., 9, 929, 10.1177/135965350400900610 Hauser, 2005, ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporin-related nephrotoxicity after renal transplantation, J. Am. Soc. Nephrol., 16, 16, 10.1681/ASN.2004100882 Saitoh, 2005, An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children, AIDS, 19, 371, 10.1097/01.aids.0000161766.13782.2f Winzer, 2005, No influence of the P-glycoprotein polymorphisms MDR1 G2677T/A and C3435T on the virological and immunological response in treatment naive HIV-positive patients, Ann. Clin. Microbiol. Antimicro., 4, 3, 10.1186/1476-0711-4-3 Bell, 1987, Chromosomal location of human P-glycoprotein gene sequences, Cancer Genet. Cytogenet., 25, 141, 10.1016/0165-4608(87)90169-5 Kioka, 1989, P-glycoprotein gene (MDR1) cDNA from human adrenal: normal P-glycoprotein carries Gly 185 with an altered pattern of multidrug resistance, Biochem. Biophys. Res. Commun., 162, 224, 10.1016/0006-291X(89)91985-2 Mickley, 1998, Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors, Blood, 91, 1749, 10.1182/blood.V91.5.1749 Ito, 2001, Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects, Pharmacogenetics, 11, 175, 10.1097/00008571-200103000-00008 Lindell, 2003, Variable expression of CYP and Pgp genes in the human small intestine, Eur. J. Clin. Invest., 33, 493, 10.1046/j.1365-2362.2003.01154.x Chaudhary, 1992, Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes, Blood, 80, 2735, 10.1182/blood.V80.11.2735.bloodjournal80112735 Fromm, 2004, Importance of P-glycoprotein at blood–tissue barriers, Trends Pharmacol. Sci., 25, 423, 10.1016/j.tips.2004.06.002 von Richter, 2004, Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens, Clin. Pharmacol. Ther., 75, 172, 10.1016/j.clpt.2003.10.008 Johne, 2002, Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene, Clin. Pharmacol. Ther., 72, 584, 10.1067/mcp.2002.129196 Verstuyft, 2003, Digoxin pharmacokinetics and MDR1 genetic polymorphisms, Eur. J. Clin. Pharmacol., 58, 809, 10.1007/s00228-003-0567-5 Verstuyft, 2003, Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition, Clin. Pharmacol. Ther., 73, 51, 10.1067/mcp.2003.8 Kurata, 2002, Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein, Clin. Pharmacol. Ther., 72, 209, 10.1067/mcp.2002.126177 Sakaeda, 2001, MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects, Pharm. Res., 18, 1400, 10.1023/A:1012244520615 Horinouchi, 2002, Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin, Pharm. Res., 19, 1581, 10.1023/A:1020433422259 Gerloff, 2002, MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males, Br. J. Clin. Pharmacol., 54, 610, 10.1046/j.1365-2125.2002.01691.x Goh, 2002, Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies, J. Clin. Oncol., 20, 3683, 10.1200/JCO.2002.01.025 Yi, 2004, A variant 2677A allele of the MDR1 gene affects fexofenadine disposition, Clin. Pharmacol. Ther., 76, 418, 10.1016/j.clpt.2004.08.002 Sisodiya, 2002, Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy, Brain, 125, 22, 10.1093/brain/awf002 Sills, 2005, Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment, Epilepsia, 46, 643, 10.1111/j.1528-1167.2005.46304.x Tan, 2004, Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy, Neurology, 63, 1090, 10.1212/01.WNL.0000137051.33486.C7 Wandel, 2002, Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein, Anesthesiology, 96, 913, 10.1097/00000542-200204000-00019 Yu, 1999, The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions, J. Clin. Pharmacol., 39, 1203, 10.1177/00912709922012006 Mai, 2003, MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporin in renal transplant patients, J. Clin. Pharmacol., 43, 1101, 10.1177/0091270003257222 Ioannidis, 2001, Replication validity of genetic association studies, Nat. Genet., 29, 306, 10.1038/ng749 Cardon, 2003, Population stratification and spurious allelic association, Lancet, 361, 598, 10.1016/S0140-6736(03)12520-2 Kullak-Ublick, 2003, ABC transporter regulation by bile acids: where PXR meets FXR, J. Hepatol., 39, 628, 10.1016/S0168-8278(03)00397-0 Tirona, 2003, Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation, J. Pharmacol. Exp. Ther., 304, 223, 10.1124/jpet.102.043026 Hustert, 2001, Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4, Drug Metab. Dispos., 29, 1454 Koyano, 2004, Functional characterization of four naturally occurring variants of human pregnane X receptor (PXR): one variant causes dramatic loss of both DNA binding activity and the transactivation of the CYP3A4 promoter/enhancer region, Drug Metab. Dispos., 32, 149, 10.1124/dmd.32.1.149 Zhang, 2001, The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants, Pharmacogenetics, 11, 555, 10.1097/00008571-200110000-00003 Tang, 2002, Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations, Pharmacogenetics, 12, 437, 10.1097/00008571-200208000-00004 Soranzo, 2004, Identifying candidate causal variants responsible for altered activity of the ABCB1 multidrug resistance gene, Genome Res., 14, 1333, 10.1101/gr.1965304 Furuno, 2002, Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to parkinson's disease, Pharmacogenetics, 12, 529, 10.1097/00008571-200210000-00004 Chowbay, 2003, Genetic polymorphisms in MDR1 and CYP3A4 genes in asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients, Pharmacogenetics, 13, 89, 10.1097/00008571-200302000-00005 Sai, 2003, Haplotype analysis of ABCB1/MDR1 blocks in a japanese population reveals genotype-dependent renal clearance of irinotecan, Pharmacogenetics, 13, 741, 10.1097/00008571-200312000-00005 Ozawa, 2004, Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1, Drug Metab. Pharmacokinet., 19, 83, 10.2133/dmpk.19.83 Sugie, 2004, Possible involvement of the drug transporters P-glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin, Antimicrob. Agents Chemother., 48, 809, 10.1128/AAC.48.3.809-814.2004 Scheffer, 2000, Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies, Cancer Res., 60, 5269 Elferink, 2002, Genetic defects in hepatobiliary transport, Biochim. Biophys. Acta, 1586, 129, 10.1016/S0925-4439(01)00103-X Itoda, 2002, Polymorphisms in the ABCC2 (cMOAT/MRP2) gene found in 72 established cell lines derived from Japanese individuals: an association between single nucleotide polymorphisms in the 5′-untranslated region and exon 28, Drug Metab. Dispos., 30, 363, 10.1124/dmd.30.4.363 Wang, 2004, Linkage disequilibrium and haplotype architecture for two ABC transporter genes (ABCC1 and ABCG2) in Chinese population: implications for pharmacogenomic association studies, Ann. Hum. Genet., 68, 563, 10.1046/j.1529-8817.2003.00124.x Dazert, 2003, Expression and localization of the multidrug resistance protein 5 (MRP5/ABCC5), a cellular export pump for cyclic nucleotides, in human heart, Am. J. Pathol., 163, 1567, 10.1016/S0002-9440(10)63513-4 Hirouchi, 2004, Characterization of the cellular localization, expression level, and function of SNP variants of MRP2/ABCC2, Pharm. Res., 21, 742, 10.1023/B:PHAM.0000026422.06207.33 Lee, 2004, Identification and functional characterization of the natural variant MRP3-Arg1297His of human multidrug resistance protein 3 (MRP3/ABCC3), Pharmacogenetics, 14, 213, 10.1097/00008571-200404000-00001 Keitel, 2003, A common dubin-johnson syndrome mutation impairs protein maturation and transport activity of MRP2 (ABCC2), Am. J. Physiol. Gastrointest. Liver Physiol., 284, G165, 10.1152/ajpgi.00362.2002 Hulot, 2005, A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination, Pharmacogenet. Genomics, 15, 277, 10.1097/01213011-200505000-00002 Suzuki, 2002, Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition, Adv. Drug Deliv. Rev., 54, 1311, 10.1016/S0169-409X(02)00075-3 Machida, 2005, Mutational analysis of the MRP2 gene and long-term follow-up of Dubin-Johnson syndrome in Japan, J. Gastroenterol., 40, 366, 10.1007/s00535-004-1555-y G. Kullak-Ublick, R. Kerb, B. Müllhaupt, E. Renner, A. Penger, U. Brinkman, et al., A novel R432T mutation in the bile salt export pump gene (BSEP; ABCB11) is associated with recurrent hitrahepatic cholestasis in an adolescent patient, Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Dallas: Abstract: 41266, 2001. Leabman, 2003, PharmGKB update: I. Genetic variants of the organic cation transporter 2 (OCT2, SLC22A2), Pharmacol. Rev., 55, 399, 10.1124/pr.55.3.6 Fukushima-Uesaka, 2004, Fourteen novel single nucleotide polymorphisms in the SLC22A2 gene encoding human organic cation transporter (OCT2), Drug Metab. Pharmacokinet., 19, 239, 10.2133/dmpk.19.239 Shu, 2004, PharmGKB update: III. Genetic variants of SLC22A1, solute carrier family 22 (organic cation transporter), member 1, Pharmacol. Rev., 56, 161, 10.1124/pr.56.2.2 Hsiang, 1999, A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters, J. Biol. Chem., 274, 37161, 10.1074/jbc.274.52.37161 Ho, 2005, Multiple OATP transporters mediate the cellular uptake of rosuvastatin, Clin. Pharmacol. Ther., 77, P64, 10.1016/j.clpt.2004.12.136 Cvetkovic, 1999, OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine, Drug Metab. Dispos., 27, 866 Kullak-Ublick, 2001, Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver, Gastroenterology, 120, 525, 10.1053/gast.2001.21176 Morimoto, 2004, A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy, Drug Metab. Pharmacokinet., 19, 453, 10.2133/dmpk.19.453 Letschert, 2004, Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8), Pharmacogenetics, 14, 441, 10.1097/01.fpc.0000114744.08559.92 Lee, 2005, Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry, J. Biol. Chem., 280, 9610, 10.1074/jbc.M411092200 Shu, 2003, Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1, Proc. Natl Acad. Sci. USA, 100, 5902, 10.1073/pnas.0730858100 Leabman, 2002, Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function, Pharmacogenetics, 12, 395, 10.1097/00008571-200207000-00007 Sekine, 2000, The multispecific organic anion transporter (OAT) family, Pflugers Arch., 440, 337, 10.1007/s004240000297 Fujita, 2005, Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1), Pharmacogenet. Genomics, 15, 201, 10.1097/01213011-200504000-00003 Jonker, 2001, Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene, Mol. Cell. Biol., 21, 5471, 10.1128/MCB.21.16.5471-5477.2001 Dresser, 2000, Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition, Clin. Pharmacokinet., 38, 41, 10.2165/00003088-200038010-00003 Zhang, 2000, Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system, Drug Metab. Dispos., 28, 329 van Montfoort, 2001, Comparison of ‘type I’ and ‘type II’ organic cation transport by organic cation transporters and organic anion-transporting polypeptides, J. Pharmacol. Exp. Ther., 298, 110 Umbenhauer, 1997, Identification of a P-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism, Toxicol. Appl. Pharmacol., 146, 88, 10.1006/taap.1997.8225 Mealey, 2001, Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene, Pharmacogenetics, 11, 727, 10.1097/00008571-200111000-00012 Pauli-Magnus, 2004, Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1), Pharm. Res., 21, 904, 10.1023/B:PHAM.0000029276.21063.0b Siegsmund, 2002, Association of the P-glycoprotein transporter MDR1 (C3435T) polymorphism with the susceptibility to renal epithelial tumors, J. Am. Soc. Nephrol., 13, 1847, 10.1097/01.ASN.0000019412.87412.BC Woodahl, 2004, Multidrug resistance gene G1199A polymorphism alters efflux transport activity of P-glycoprotein, J. Pharmacol. Exp. Ther., 310, 1199, 10.1124/jpet.104.065383 Balram, 2003, Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic–genotypic correlates, Br. J. Clin. Pharmacol., 56, 78, 10.1046/j.1365-2125.2003.01820.x Min, 2002, C3435T mutation in exon 26 of the human MDR1 gene and cyclosporin pharmacokinetics in healthy subjects, Ther. Drug Monit., 24, 400, 10.1097/00007691-200206000-00012 Yates, 2003, The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporin oral disposition in renal transplant patients, J. Clin. Pharmacol., 43, 555, 10.1177/0091270003253617 von Ahsen, 2001, No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted Cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients, Clin. Chem., 47, 1048, 10.1093/clinchem/47.6.1048 Hesselink, 2003, Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporin and tacrolimus, Clin. Pharmacol. Ther., 74, 245, 10.1016/S0009-9236(03)00168-1 Haufroid, 2004, The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporin and tacrolimus dose requirements and trough blood levels in stable renal transplant patients, Pharmacogenetics, 14, 147, 10.1097/00008571-200403000-00002 Mathijssen, 2003, Irinotecan pathway genotype analysis to predict pharmacokinetics, Clin. Cancer Res., 9, 3246 Skarke, 2003, Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers, Pharmacogenetics, 13, 651, 10.1097/00008571-200311000-00001 Pauli-Magnus, 2003, No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects, Clin. Pharmacol. Ther., 74, 487, 10.1016/S0009-9236(03)00234-0 Kerb, 2001, The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels, Pharmacogenomics J., 1, 204, 10.1038/sj.tpj.6500025 Wong, 2005, Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer, Clin. Pharmacol. Ther., 77, 33, 10.1016/j.clpt.2004.09.002 Zheng, 2003, Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms, Am. J. Transplant., 3, 477, 10.1034/j.1600-6143.2003.00077.x Macphee, 2002, Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate dose requirement, Transplantation, 74, 1486, 10.1097/00007890-200212150-00002 Anglicheau, 2003, Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients, J. Am. Soc. Nephrol., 14, 1889, 10.1097/01.ASN.0000073901.94759.36 Goto, 2004, CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation, Pharmacogenetics, 14, 471, 10.1097/01.fpc.0000114747.08559.49 MacPhee, 2004, The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation, Am. J. Transplant., 4, 914, 10.1111/j.1600-6143.2004.00435.x Tsuchiya, 2004, Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients, Transplantation, 78, 1182, 10.1097/01.TP.0000137789.58694.B4 Plasschaert, 2004, Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia, Clin. Pharmacol. Ther., 76, 220, 10.1016/j.clpt.2004.05.007 Zheng, 2004, The impact of pharmacogenomic factors on steroid dependency in pediatric heart transplant patients using logistic regression analysis, Pediatr. Transplant., 8, 551, 10.1111/j.1399-3046.2004.00223.x Yamauchi, 2002, Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene, Transplantation, 74, 571, 10.1097/00007890-200208270-00024 Anglicheau, 2004, CYP3A5 and MDR1 genetic polymorphisms and cyclosporin pharmacokinetics after renal transplantation, Clin. Pharmacol. Ther., 75, 422, 10.1016/j.clpt.2004.01.009 Nozawa, 2005, Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms, Drug Metab. Dispos., 33, 434, 10.1124/dmd.104.001909 Conrad, 2002, A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance, Pharmacogenetics, 12, 321, 10.1097/00008571-200206000-00008 Bonhomme-Faivre, 2004, MDR-1 C3435T polymorphism influences cyclosporine a dose requirement in liver-transplant recipients, Transplantation, 78, 21, 10.1097/01.TP.0000130981.55654.78 Hesselink, 2004, Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes, Clin. Pharmacol. Ther., 76, 545, 10.1016/j.clpt.2004.08.022 Puisset, 2004, Dexamethasone as a probe for docetaxel clearance, Cancer Chemother. Pharmacol., 54, 265, 10.1007/s00280-004-0823-0 Mathijssen, 2004, Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes, J. Natl Cancer Inst., 96, 1585, 10.1093/jnci/djh298 Eap, 2004, CYP3A activity measured by the midazolam test is not related to 3435 C >T polymorphism in the multiple drug resistance transporter gene, Pharmacogenetics, 14, 255, 10.1097/00008571-200404000-00005 Colombo, 2005, Swiss HIV cohort study. Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo, Pharmacogenet. Genomics, 15, 599, 10.1097/01.fpc.0000172241.42546.d3 Zheng, 2004, Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism, J. Clin. Pharmacol., 44, 135, 10.1177/0091270003262108 Mai, 2004, MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients, Br. J. Clin. Pharmacol., 58, 548, 10.1111/j.1365-2125.2004.02182.x Nasi, 2003, MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients, AIDS, 17, 1696, 10.1097/00002030-200307250-00016 Verstuyft, 2005, Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy, AIDS, 19, 2127, 10.1097/01.aids.0000196122.91633.04 Haas, 2005, Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an adult AIDS clinical trials group study, J. Infect. Dis., 192, 1931, 10.1086/497610 Roberts, 2002, A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression, Pharmacogenomics J., 2, 191, 10.1038/sj.tpj.6500099